Forest Laboratories’ investigational drug for treating neuropathic pain associated with diabetic peripheral neuropathy has failed to meet the primary endpoint of its Phase II trial.

Radiprodil (RGH-896) did not demonstrate clinically meaningful reductions in mean daily pain scores compared to a placebo for any dosage studied.

The trial involved 458 adults with diabetic peripheral neuropathy, who were randomised to one of three radiprodil doses (15mg, 30mg or 45mg), an active comparator or a placebo, three times a day for 14 weeks.

The most common adverse events after treatment with radiprodil were dizziness, fatigue and insomnia.

Radiprodil is an orally active NR2B (a sub-unit of the NMDA receptor) antagonist discovered by Gedeon Richter, who are co-developing the drug with Forest Laboratories.

The two companies will review the study again to plan the next steps in development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.